Market Overview

UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Approval

Related BIIB
Deutsche Bank Analyst Talks Up Biogen On CNBC; Stock Responds Slightly
Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector
Don't Panic Over Recent Tech Turmoil (Fox Business)

In a report published Thursday, Canaccord Genuity analyst Ritu Baral reiterated a Buy rating on Biogen Idec (NASDAQ: BIIB), and raised the price target from $187.00 to $200.00.

In the report, Baral noted, “Reiterate BUY, increasing target to $200 on approval of Tecfidera (Tec), BIIB's new blockbuster potential oral MS drug with sparkling clean label. BIIB guidance implies strong confidence in the Tec launch. We have confidence in the initial phase of launch on high levels of community patient warehousing.We see long-term value and blockbuster potential in Tec, Tysabri and the hemophilia franchise. Our $200 price target is DCF-based.”

Biogen Idec closed on Wednesday at $182.68.

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (BIIB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free